Research Article

Laboratory Investigation (2005) 85, 921–931. doi:10.1038/labinvest.3700292 Published online 2 May 2005

Patterns of gene amplification in gastrointestinal stromal tumors (GIST)

Luigi Tornillo1, Giacomo Duchini1, Vincenza Carafa1, Alessandro Lugli1, Stefan Dirnhofer1, Dolores Di Vizio2, Amedeo Boscaino3, Rosanna Russo4, Coya Tapia1, Regine Schneider-Stock5, Guido Sauter1, Luigi Insabato2 and Luigi M Terracciano1,2

  1. 1Institute of Pathology, University of Basel, Switzerland
  2. 2Department of Biomorphological and Functional Sciences, University 'Federico II' of Naples, Italy
  3. 3Operative Unit of Pathology, 'Antonio Cardarelli' Hospital, Naples, Italy
  4. 4Operative Unit of Pathology, 'San Leonardo' Hospital, Salerno, Italy
  5. 5Department of Pathology, Otto-von-Guericke University, Magdeburg, Germany

Correspondence: Dr L Tornillo, MD, Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland. E-mail: tornillol@uhbs.ch

Received 9 September 2004; Revised 21 March 2005; Accepted 22 March 2005; Published online 2 May 2005.

Top

Abstract

Gastrointestinal stromal tumors (GIST) are the most common primary mesenchymal tumors of the gastrointestinal tract (GIT). They represent a wide clinico-pathological spectrum of tumors. No single histological or clinical parameter can predict the prognosis while the response to therapy is related to the type of KIT or PDGFRA mutation. Cytogenetic and CGH studies have identified frequent gross chromosomal aberrations but the target genes of these changes are unknown. To determine whether known oncogenes take part in genomic rearrangements and to investigate the potential clinical significance of their amplifications, nine known oncogenes (CMYC, MDM2, GLI1, CDK4, HER2, EGFR1, CCND1, FGF3, EMS) were analyzed by fluorescent in situ hybridization (FISH) on a tissue microarray (TMA) containing 94 primary GIST. Clinical follow-up information was available for 57 of these patients. Amplification was found for CMYC in three of 90 (3.3%), for MDM2 in five of 94 (5.3%), for EGFR1 in five of 94 (5.3%), and for CCND1 in seven of 79 (8.9%) evaluable cases. No amplifications were seen for HER2, GLI1, CDK4, FGF3, and EMS. Amplifications of MDM2 and CCND1 were associated with clinical and histological malignancy. In conclusion, our data show that gene amplification does occur in a subset of GIST. Identification of MDM2/CCND1 amplification may represent another molecular feature that could help in the evaluation of the behavior of GISTs.

Keywords:

GIST, FISH, TMA, amplification, MDM2, HER2, EGFR1, CCND1

Extra navigation

.

naturejobs

natureproducts


ADVERTISEMENT